Cite
Shah NP, Wang Q, Wolski KE, et al. The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care. 2019;43(2):e22-e24doi: 10.2337/dc19-1117.
Shah, N. P., Wang, Q., Wolski, K. E., Cho, L., McErlean, E., Ruotolo, G., Weerakkody, G., Riesmeyer, J. S., Nicholls, S. J., Lincoff, A. M., Nissen, S. E., & Menon, V. (2020). The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes care, 43(2), e22-e24. https://doi.org/10.2337/dc19-1117
Shah, Nishant P, et al. "The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE." Diabetes care vol. 43,2 (2020): e22-e24. doi: https://doi.org/10.2337/dc19-1117
Shah NP, Wang Q, Wolski KE, Cho L, McErlean E, Ruotolo G, Weerakkody G, Riesmeyer JS, Nicholls SJ, Lincoff AM, Nissen SE, Menon V. The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care. 2020 Feb;43(2):e22-e24. doi: 10.2337/dc19-1117. Epub 2019 Dec 05. PMID: 31806654.
Copy
Download .nbib